International Council on Nanotechnology

ICON Web & News Virtual Journal Everything

Resources
	Virtual Journal
	Analyze Database
	GoodNanoGuide
	ICON Reports
	ICON Backgrounders
	Glossary
	Policy Reports
	Ratings Comment Guidelines
	Links

Quick Search:
Keywords: Search: Search Using OECD Database

Details

Return to Previous Page

Addition or Correction

Title:

Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease

Date:

11/2005

Link to Journal Abstract

Abstract:

Alzheimer's disease (AD) is the most common cause of dementia among the elderly, affecting 5% of Americans over age 65, and 20% over age 80. An excess of senile plaques (beta-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. Unfortunately, targeted drug delivery to the central nervous system (CNS), for the therapeutic advancement of neurodegenerative disorders such as Alzheimer's, is complicated by restrictive mechanisms imposed at the blood-brain barrier (BBB). Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. This review gives an account of the BBB and discusses the literature on biodegradable polymeric nanoparticles (NPs) with appropriate surface modifications that can deliver drugs of interest beyond the BBB for diagnostic and therapeutic applications in neurological disorders, such as AD. The physicochemical properties of the NPs at different surfactant concentrations, stabilizers, and amyloid-affinity agents could influence the transport mechanism.

Non-technical Summary:

Good review of blood-brain barrier and good figures.

Content Emphasis

Peer Reviewed Journal Article

Target Audience

Technical Research

Citation:

J Control Release. 2005 Nov 28;108(2-3):193-214. Epub 2005 Oct 24

Publication:

Journal of Controlled Release

Author:

Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN,